Abstract | AIM: MATERIALS AND METHODS: Forty one pediatric outpatients (27 females, mean age 14.5 +/- 1.4 ys) with H. pylori-associated chronic gastritis who underwent endoscopy for dyspeptic symptoms received the combination of bismuth subcitrate (8/mg/kg/day, q. d. s.) for 14 days, rifaximin (800 mg/day) for 10 days and furazolidone (10 mg/kg/day, q. d. s.) or nifuratel (15 mg/kg/two times daily) for 10 days. H. pylori status was determined before the treatment by modified Giemsa staining/ urease test and after the treatment (in 4-6 weeks) by ammonia breath test. RESULTS: H. pylori was eradicated in 35 children (85.4%; 95% CI: 75.4-96.4 ITT and PP tests). There were no serious adverse reactions and were no withdrawals due to any side effects. CONCLUSION:
|
Authors | A A Nizhevich, P L Shcherbakov, É N Akhmadeeva, R Sh Khasanov |
Journal | Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology
(Eksp Klin Gastroenterol)
Issue 1
Pg. 85-7
( 2011)
ISSN: 1682-8658 [Print] Russia (Federation) |
PMID | 21560396
(Publication Type: Journal Article)
|
Chemical References |
- Anti-Infective Agents
- Organometallic Compounds
- Rifamycins
- Furazolidone
- bismuth tripotassium dicitrate
- Rifaximin
|
Topics |
- Adolescent
- Anti-Infective Agents
(administration & dosage, adverse effects)
- Child
- Drug Therapy, Combination
(methods)
- Female
- Furazolidone
(administration & dosage, adverse effects)
- Helicobacter Infections
(drug therapy)
- Helicobacter pylori
- Humans
- Male
- Organometallic Compounds
(administration & dosage, adverse effects)
- Rifamycins
(administration & dosage, adverse effects)
- Rifaximin
|